Literature DB >> 11748267

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.

S J Choi1, Y Oba, Y Gazitt, M Alsina, J Cruz, J Anderson, G D Roodman.   

Abstract

We recently identified macrophage inflammatory protein 1-alpha (MIP-1alpha) as a factor produced by multiple myeloma (MM) cells that may be responsible for the bone destruction in MM (1). To investigate the role of MIP-1alpha in MM bone disease in vivo, the human MM-derived cell line ARH was stably transfected with an antisense construct to MIP-1alpha (AS-ARH) and tested for its capacity to induce MM bone disease in SCID mice. Human MIP-1alpha levels in marrow plasma from AS-ARH mice were markedly decreased compared with controls treated with ARH cells transfected with empty vector (EV-ARH). Mice treated with AS-ARH cells lived longer than controls and, unlike the controls, they showed no radiologically identifiable lytic lesions. Histomorphometric analysis demonstrated that osteoclasts (OCLs) per square millimeter of bone and OCLs per millimeter of bone surface of AS-ARH mice were significantly less than in EV-ARH mice, and the percentage of tumors per total bone area was also significantly decreased. AS-ARH cells demonstrated decreased adherence to marrow stromal cells, due to reduced expression of the alpha(5)beta(1) integrin and diminished homing capacity and survival. These data support an important role for MIP-1alpha in cell homing, survival, and bone destruction in MM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748267      PMCID: PMC209465          DOI: 10.1172/JCI13116

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Regulation of monocyte integrin expression by beta-family chemokines.

Authors:  K Vaddi; R C Newton
Journal:  J Immunol       Date:  1994-11-15       Impact factor: 5.422

2.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.

Authors:  G D Roodman; N Kurihara; Y Ohsaki; A Kukita; D Hosking; A Demulder; J F Smith; F R Singer
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

3.  Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures.

Authors:  N Kurihara; C Chenu; M Miller; C Civin; G D Roodman
Journal:  Endocrinology       Date:  1990-05       Impact factor: 4.736

4.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.

Authors:  J H Han; S J Choi; N Kurihara; M Koide; Y Oba; G D Roodman
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

5.  Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment.

Authors:  T Kukita; H Nomiyama; Y Ohmoto; A Kukita; T Shuto; T Hotokebuchi; Y Sugioka; R Miura; T Iijima
Journal:  Lab Invest       Date:  1997-03       Impact factor: 5.662

6.  Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

Authors:  C M Shipman; M J Rogers; J F Apperley; R G Russell; P I Croucher
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

7.  Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts.

Authors:  K Fuller; J M Owens; T J Chambers
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

8.  Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines.

Authors:  I Kim; H Uchiyama; D Chauhan; K C Anderson
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

9.  Development of an in vivo model of human multiple myeloma bone disease.

Authors:  M Alsina; B Boyce; R D Devlin; J L Anderson; F Craig; G R Mundy; G D Roodman
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

10.  Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway.

Authors:  M A del Pozo; P Sánchez-Mateos; M Nieto; F Sánchez-Madrid
Journal:  J Cell Biol       Date:  1995-10       Impact factor: 10.539

View more
  50 in total

1.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 2.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

4.  MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Authors:  Sonia Vallet; Noopur Raje; Kenji Ishitsuka; Teru Hideshima; Klaus Podar; Shweta Chhetri; Samantha Pozzi; Iris Breitkreutz; Tanyel Kiziltepe; Hiroshi Yasui; Enrique M Ocio; Norihiko Shiraishi; Janice Jin; Yutaka Okawa; Hiroshi Ikeda; Siddhartha Mukherjee; Nileshwari Vaghela; Diana Cirstea; Marco Ladetto; Mario Boccadoro; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

Review 5.  Metastasis and bone loss: advancing treatment and prevention.

Authors:  Robert E Coleman; Allan Lipton; G David Roodman; Theresa A Guise; Brendon F Boyce; Adam M Brufsky; Philippe Clézardin; Peter I Croucher; Julie R Gralow; Peyman Hadji; Ingunn Holen; Gregory R Mundy; Matthew R Smith; Larry J Suva
Journal:  Cancer Treat Rev       Date:  2010-05-15       Impact factor: 12.111

Review 6.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

Review 7.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

8.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

9.  The ecology of cancer from an evolutionary game theory perspective.

Authors:  Jorge M Pacheco; Francisco C Santos; David Dingli
Journal:  Interface Focus       Date:  2014-08-06       Impact factor: 3.906

10.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.